Insulet (NSDQ:PODD) shares are under pressure this morning after the diabetes company missed expectations for its 4th-quarter earnings, despite beating Wall Street’s consensus sales forecast.
Billerica, Mass.-based Insulet narrowed its losses by -66.6%, to -$9.1 million, or -16¢ per share, on sales growth of 23.6% to $103.6 million for the 3 months ended Dec. 31, compared with Q4 2015. Analysts on The Street were looking for losses of just -6¢ on sales of $100.6 million.
